Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Stock Information for Tenaya Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tenaya Therapeutics Inc.

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Tenaya Therapeutics Presents Interim Data from RIDGE(TM) Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK(TM)-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Tenaya Therapeutics Announces Pricing of Public Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.